Company Announcement / Press release Archives - Page 12 of 16

Xspray Pharma publishes Interim report Q1, January – March 2020

“This year is an important year for Xspray. I expect that the amorphous material provided by our unique production facility will provide positive clinical data, which is a prerequisite for us to apply for market approval for HyNap-Dasa in the U.S. This means that we together with a partner who either buys or licenses the […]

Xspray Pharma provides an update on how the Covid-19 pandemic affects the company’s planned clinical studies

STOCKHOLM – April 15, 2020. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces that the start of the pivotal clinical bioequivalence studies with HyNap-Dasa are expected to be postponed by two to three months due to the Covid-19 pandemic. Xspray Pharma's planned clinical trials are, like the trials of many other drug developing companies, affected by […]

XSpray: Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 14 May 2020 at 11.00 CEST at Advokatfirman Vinge's office on Stureplan 8 in Stockholm. Registration starts at 10.30 CEST. Due to the current pandemic (covid-19), Xspray has taken a number of precautionary measures ahead of […]

Trading in Xspray Pharma’s shares commences today on Nasdaq Stockholm

STOCKHOLM – March 27, 2020. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today the commencement of trading in the company’s shares on Nasdaq Stockholm's main market. “We are very excited about the move to the main market. This is a natural step as we approach a new phase in the company's development and move towards commercialization of […]

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

Press release, Solna on 26 March 2020 The following resolution was passed at the extraordinary general meeting in Xspray Pharma AB (publ) today, on 26 March 2020. Adoption of incentive programme The extraordinary general meeting resolved, in accordance with the board’s proposal, to adopt a long-term incentive programme for a number of employees of Xspray. According […]

The conditions for Xspray Pharma’s listing on Nasdaq Stockholm have been fulfilled

STOCKHOLM – March 26, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020, that the company had received clearance for a listing on Nasdaq Stockholm, following the fulfilment of customary conditions. Xspray Pharma has today received information that the conditions have been fulfilled and accordingly, Xspray Pharma’s first day of trading on […]

Xspray Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

STOCKHOLM – March 23, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020 that Nasdaq Stockholm’s listing committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on 23 March, the prospectus that has been prepared by the company in connection with the listing was […]

Xspray Pharma approved for listing on Nasdaq Stockholm

STOCKHOLM – March 18, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that Nasdaq Stockholm’s listing committee has approved the company’s application to be listed on Nasdaq Stockholm’s main market. The approval is conditional upon the fulfilment of customary conditions, among others that a prospectus is approved and registered by the Swedish Financial Supervisory […]

Xspray receives notification of manufacturing approval and provides update on clinical studies

STOCKHOLM – March 17, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces today that its production partner, Nerpharma, has received approval from Italian Medicines Agency (AIFA) for the full-scale production facility in Milan, Italy. The approval applies to clinical trial use ofamorphous material based on the company’s HyNap technology. The company also announces […]

Xspray Pharma publishes Interim report Q4, January – December 2019

PRESS RELEASE February 28, 2020 “One important milestone was reached in June when our production facility in Italy was completed and was able to do a test run. We have now proven that our technology is possible to scale up – and we are the first in the world to manufacture amorphous material in the […]